Laurence de Schoulepnikoff

Laurence is a seasoned pharma/biotech professional with over 25 years of experience in transactions and R&D operations and general management. She has worked in VC funded biotech start-ups, mid-size private companies as well as large corporate organizations. Prior to joining Tridek-One, Laurence was COO and CBO of AMAL Therapeutics, a leading Swiss biotechnology company focused on therapeutic cancer vaccines acquired by Boehringer Ingelheim in 2019. 

Laurence holds a Master in Chemical Engineering from the Ecole Polytechnique Fédérale of Lausanne (EPFL).  

She is a Venture Partner at AdBio Partners, seats as independent board member in biotech start-ups and is a board member of the Swiss Healthcare Licensing Group (HLG).